Clinicopathological significance of $p15$ promoter hypermethylation in multiple myeloma: a meta-analysis

Bing Wei
Shuhua Yang
Bo Zhang
Yong Feng

Department of Orthopaedic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China

Abstract: Published studies reported that loss of function of the $p15^{INK4b}$ gene is caused by hypermethylation; however, whether or not the inactivation is associated with the incidence and clinical significance of multiple myeloma (MM) remains unclear. In this study, we performed a meta-analysis to quantitatively determine the effects of $p15$ hypermethylation on the incidence of MM. The related research articles in English and Chinese languages were evaluated. The data were extracted and assessed independently. The pooled data were analyzed and odds ratios were calculated and summarized. Sixteen eligible studies were selected for final analysis. We demonstrated that $p15$ hypermethylation is significantly higher in MM than that in normal bone marrow, as well as monoclonal gammopathy of undetermined significance. However, aberrant $p15$ hypermethylation was not significantly higher in advanced MM than that in early-stage MM. The results of this study reveal that $p15$ hypermethylation is correlated with an increased risk in the progression of monoclonal gammapathy of undetermined significance to MM. $p15$ hypermethylation, which induces the loss of function of the $p15$ gene, plays a critical role in the early tumorigenesis of MM and serves as a reputable diagnostic marker and potential drug target.

Keywords: $p15^{INK4b}$, methylation, asymptomatic monoclonal gammopathy of undetermined significance, tumor suppressor gene, odds ratio, meta-analysis

Introduction

Multiple myeloma (MM) is a clonal malignancy characterized by the production of monoclonal immunoglobulin and the proliferation of malignant plasma cells in the bone marrow. Clinically, MM starts with immortalization of a post-germinal center B cell and presents as asymptomatic monoclonal gammopathy of undetermined significance (MGUS). MGUS plasma cells share many abnormal characteristics with MM plasma cells. MGUS is considered as the precursor of MM, since it is able to progress to symptomatic MM at a rate of 1% per year. Over the years, newly approved drugs such as bortezomib, lenalidomide, and thalidomide have shown significant benefits in symptomatic MM at a rate of 1% per year.

Microsatellite instability and CpG island methylator phenotype (CIMP) are associated with hypermethylation, which induces the loss of function of the $p15$ gene. Inactivation of $p15$ can be caused by aberrant CpG island methylation, which has been confirmed in MM. In early-stage MM, the clinicopathological significance of $p15$ promoter hypermethylation is not significant, whereas in advanced MM, the prevalence of $p15$ promoter hypermethylation is significantly higher than that in MGUS. Although the proportion of $p15$ promoter hypermethylation in advanced MM is significantly higher than that in MGUS, the role of $p15$ gene inactivation in MM is not clear.

Therefore, the identification of biomarker and potential drug target is still necessary to improve the survival rate in patients who are refractory to chemotherapy. Epigenetic alteration, particularly aberrant DNA methylation, is one of the best-characterized epigenetic modifications contributing to tumor initiation, progression, and prognosis. CpG islands of tumor suppressor genes are aberrantly methylated (hypermethylation), which result in transcriptional repression and loss of function of genes in many tumors.
including MM.\textsuperscript{10–12} The \textit{p15}, as a tumor suppression gene, is hypermethylated in many tumors including MM.

\textit{p15}\textsuperscript{INK4A} (p15), one of the INK4 members, is a cyclin-dependent kinase inhibitor.\textsuperscript{13,14} Previously, \textit{p15}\textsuperscript{INK4A}, as well as other INK4 members, \textit{p14}\textsuperscript{ARF}, \textit{p16}\textsuperscript{INK4A}, \textit{p21}\textsuperscript{CIP1}, and \textit{p27}\textsuperscript{KIP2}, have been revealed to be involved in the neoplastic process of carcinomas.\textsuperscript{15,16} Although a number of reports have determined that the inactivation of \textit{p15} gene is mainly induced by hypermethylation in MM, the reported rates of \textit{p15} hypermethylation in MM are remarkably diverse. In addition, whether or not the inactivation of \textit{p15} gene is associated with the incidence and clinical significance of MM has not been thoroughly determined. Hence, we performed a systematic review and meta-analysis to determine the effects of \textit{p15} hypermethylation on the incidence and clinical significance of MM.

Methods

Search strategy and selection criteria

We identified studies from Embase, ISI web, and PubMed from August 1, 1995 to July, 2015 using the following search terms: “multiple myeloma”, “Kahler’s disease”, “plasma cell myeloma”, “methylation”, “\textit{p15}”, “\textit{p15}\textsuperscript{INK4A}”, and “cyclin-dependent kinase inhibitor 2B”. We also manually searched reviews for additional related articles and the reference lists of the retrieved articles. We only took into account the studies published in the English and Chinese languages for full-text reading and final evaluations. After the exclusion of redundant and/or nonrelevant publications from different databases, the remaining articles were analyzed and evaluated in the full-text version for inclusion and exclusion criteria.

To be eligible, a study needed to meet the following criteria: 1) \textit{p15} methylation evaluated in primary MM; 2) \textit{p15} methylation determined by polymerase chain reaction (PCR); 3) research revealed the relationship between \textit{p15} methylation of MM clinicopathological parameters and prognosis; and 4) studies provided sufficient data and information to determine odds ratio (OR). The exclusion criteria included: 1) case reports, conference abstracts, letters, reviews, editorials, and expert opinion; and 2) all publications regarding in vitro/ex vivo studies, cell lines, and human xenografts. In addition to inclusion criteria, “aberrant” \textit{p15} methylation or \textit{p15} hypermethylation is defined by clear PCR product band detected by methylation-specific polymerase chain reaction (MSP).

Data extraction and methodological assessment

Two authors (BW, SY) independently reviewed and extracted data from eligible studies. Two authors (BZ, YF) reviewed all the articles that fit the inclusion and exclusion criteria. Disagreements were resolved through discussion and consensus. For each study, the following information was recorded: year of publication, the first author name, number of cases, sample source, methylation detection method, clinicopathological parameters, methylation rate, and follow-up results. Heterogeneity of investigations was evaluated to determine whether or not the data of the various studies could be analyzed.

Three investigators (BW, SY, and BZ) read through each publication independently for the methodological evaluation of the studies, and assessed and scored them according to the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) guidelines and European Lung Cancer Working Party (ELCWP) quality scale.\textsuperscript{17, 18} They provided the quality scores and reached a consensus value for each item.

Statistical analysis

The Review Manager 5.2 (Cochrane Collaboration, Oxford, UK) and STATA 12.0 (StataCorp LP, College Station, TX, USA) were selected for analysis. The frequency of \textit{p15} promoter hypermethylation was compared in different tumor characteristics. The pooled frequency of \textit{p15} promoter hypermethylation and 95% confidence intervals (CIs) were estimated. Cochran’s \textit{Q} test\textsuperscript{19} and the \textit{F} statistic were used for evaluating heterogeneity among studies.\textsuperscript{20, 21} A fixed-effect model was used to calculate parameters when heterogeneity was not an issue (\textit{F} values < 50%). A random-effects model was used to pool data and attempt to identify potential sources of heterogeneity based on subgroup analyses, if there was substantial heterogeneity (\textit{F} values ≥ 50%). \textit{P}-values tailed less than 0.05 were considered statistically significant.

The method reported by Egger et al was used for assessing publication bias.\textsuperscript{22} Meta-regression, subgroup analysis, and sensitivity analysis were used for exploring reasons of statistical heterogeneity. STATA version 10.0 was used for the analysis of meta-regression and publication bias.

Results

Sixteen studies published from 1997 to 2014 were included in the meta-analysis, as shown in Figure 1. A total of 607 patients from Argentina, Brazil, the People’s Republic of China, Hong Kong, France, Spain, Austria, and USA were enrolled; Table 1 showed their basic characteristics.

The meta-analysis showed that \textit{P15} hypermethylation is significantly higher in MM than that in normal bone marrow samples. The pooled OR from 15 studies, including 571 MM and 193 normal bone marrow, are shown in Figure 2 (\textit{OR}=19.80, 95% \textit{CI}=9.21–42.56, \textit{P}<0.00001), which
Clinicopathological significance of p15 promoter hypermethylation in MM

Figure 1 Flowchart of study selection.

Table I Basic characteristics of the included studies in MM

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Number of patients</th>
<th>Methods</th>
<th>Primary aim</th>
<th>Methylation site</th>
<th>p15 expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Li et al</td>
<td>People's Republic of China</td>
<td>54</td>
<td>MSP</td>
<td>Determine the methylation status of p15 gene in MM</td>
<td>Promoter, CpG islands</td>
<td>–</td>
</tr>
<tr>
<td>Stanganelli et al</td>
<td>Argentina</td>
<td>44</td>
<td>MSP</td>
<td>Determine the methylation status of p15 in the progression of MM</td>
<td>Promoter, CpG islands</td>
<td>–</td>
</tr>
<tr>
<td>Braggio et al</td>
<td>Brazil</td>
<td>68</td>
<td>MSP</td>
<td>Determine the methylation status of nine tumor suppressor genes including p15 in MM</td>
<td>Promoter, CpG islands</td>
<td>–</td>
</tr>
<tr>
<td>Martin et al</td>
<td>Spain</td>
<td>30</td>
<td>MSP</td>
<td>Determine the methylation status of six tumor suppressor genes including p15 in MM</td>
<td>Promoter, CpG islands</td>
<td>–</td>
</tr>
<tr>
<td>Jiang et al</td>
<td>People's Republic of China</td>
<td>33</td>
<td>MSP, RT-PCR</td>
<td>To explore the correlation between p15 gene methylation in pathogenesis of MM</td>
<td>First exon, CpG islands</td>
<td>+</td>
</tr>
<tr>
<td>Liang et al</td>
<td>People's Republic of China</td>
<td>28</td>
<td>MSP, RT-PCR</td>
<td>Determine the methylation status of p15 gene in MM</td>
<td>First exon, CpG islands</td>
<td>–</td>
</tr>
<tr>
<td>Chim et al</td>
<td>Hong Kong</td>
<td>13</td>
<td>MSP</td>
<td>Determine the methylation status of ten tumor suppressor genes including p15 in MM</td>
<td>Promoter, CpG islands</td>
<td>–</td>
</tr>
<tr>
<td>Seidl et al</td>
<td>Austria</td>
<td>113</td>
<td>MSP</td>
<td>Determine the methylation frequencies of ten genes including p15 in patients with monoclonal gammopathies.</td>
<td>Promoter, CpG islands</td>
<td>–</td>
</tr>
<tr>
<td>Galm et al</td>
<td>USA</td>
<td>56</td>
<td>MSP</td>
<td>Determine the methylation status of eleven tumor suppressor genes including p15 in MM</td>
<td>Promoter, CpG islands</td>
<td>–</td>
</tr>
<tr>
<td>Chen et al</td>
<td>People's Republic of China</td>
<td>22</td>
<td>MSP</td>
<td>Determine the methylation frequencies of p15 and p16 in MM</td>
<td>Promoter, CpG islands</td>
<td>–</td>
</tr>
<tr>
<td>Fu et al</td>
<td>People's Republic of China</td>
<td>42</td>
<td>MSP</td>
<td>Determine the methylation status of p15 in MM and MGUS</td>
<td>Promoter, CpG islands</td>
<td>–</td>
</tr>
<tr>
<td>Guo et al</td>
<td>People's Republic of China</td>
<td>23</td>
<td>MSP</td>
<td>Determine the methylation status of p15 in MM</td>
<td>Promoter, CpG islands</td>
<td>–</td>
</tr>
<tr>
<td>Guillerm et al</td>
<td>France</td>
<td>33</td>
<td>MSP</td>
<td>Determine p15 and p16 methylation in the progression of MM</td>
<td>Promoter, CpG islands</td>
<td>–</td>
</tr>
<tr>
<td>Wu et al</td>
<td>People's Republic of China</td>
<td>12</td>
<td>MSP</td>
<td>To study the effect of p15 hypermethylation in MM</td>
<td>Promoter, CpG islands</td>
<td>–</td>
</tr>
<tr>
<td>Ng et al</td>
<td>Hong Kong</td>
<td>12</td>
<td>MSP</td>
<td>To investigate whether p15 and p16 deactivated by deletions, mutations, and hypermethylation in MM</td>
<td>Promoter, CpG islands</td>
<td>–</td>
</tr>
</tbody>
</table>

Notes: “+” p15 protein was detected. “−” p15 protein was not detected.

Abbreviations: MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; MSP, methylation-specific polymerase chain reaction; RT-PCR, reverse transcription-polymerase chain reaction.


<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Multiple myeloma Events</th>
<th>Normal bone marrow Events</th>
<th>Weight (%)</th>
<th>Odds ratio M-H, fixed, 95% CI</th>
<th>Odds ratio M-H, fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Braggio et al&lt;sup&gt;23&lt;/sup&gt;</td>
<td>11</td>
<td>68</td>
<td>0</td>
<td>10</td>
<td>12.5</td>
</tr>
<tr>
<td>Chen et al&lt;sup&gt;24&lt;/sup&gt;</td>
<td>10</td>
<td>22</td>
<td>0</td>
<td>10</td>
<td>6.4</td>
</tr>
<tr>
<td>Chim et al&lt;sup&gt;25&lt;/sup&gt;</td>
<td>10</td>
<td>13</td>
<td>0</td>
<td>8</td>
<td>2.6</td>
</tr>
<tr>
<td>Fan et al&lt;sup&gt;26&lt;/sup&gt;</td>
<td>17</td>
<td>24</td>
<td>0</td>
<td>10</td>
<td>3.6</td>
</tr>
<tr>
<td>Fu et al&lt;sup&gt;27&lt;/sup&gt;</td>
<td>22</td>
<td>42</td>
<td>0</td>
<td>5</td>
<td>7.3</td>
</tr>
<tr>
<td>Galm et al&lt;sup&gt;28&lt;/sup&gt;</td>
<td>1</td>
<td>53</td>
<td>0</td>
<td>20</td>
<td>12.2</td>
</tr>
<tr>
<td>Guo et al&lt;sup&gt;29&lt;/sup&gt;</td>
<td>17</td>
<td>23</td>
<td>0</td>
<td>10</td>
<td>3.2</td>
</tr>
<tr>
<td>Jiang et al&lt;sup&gt;30&lt;/sup&gt;</td>
<td>24</td>
<td>33</td>
<td>0</td>
<td>20</td>
<td>3.0</td>
</tr>
<tr>
<td>Li et al&lt;sup&gt;31&lt;/sup&gt;</td>
<td>15</td>
<td>54</td>
<td>0</td>
<td>40</td>
<td>7.2</td>
</tr>
<tr>
<td>Liang et al&lt;sup&gt;32&lt;/sup&gt;</td>
<td>18</td>
<td>28</td>
<td>0</td>
<td>10</td>
<td>4.6</td>
</tr>
<tr>
<td>Martin et al&lt;sup&gt;33&lt;/sup&gt;</td>
<td>5</td>
<td>30</td>
<td>0</td>
<td>10</td>
<td>10.6</td>
</tr>
<tr>
<td>Ng et al&lt;sup&gt;34&lt;/sup&gt;</td>
<td>8</td>
<td>12</td>
<td>0</td>
<td>12</td>
<td>3.0</td>
</tr>
<tr>
<td>Seidl et al&lt;sup&gt;35&lt;/sup&gt;</td>
<td>30</td>
<td>113</td>
<td>0</td>
<td>8</td>
<td>11.8</td>
</tr>
<tr>
<td>Stanganelli et al&lt;sup&gt;36&lt;/sup&gt;</td>
<td>14</td>
<td>44</td>
<td>0</td>
<td>10</td>
<td>9.5</td>
</tr>
<tr>
<td>Wu et al&lt;sup&gt;37&lt;/sup&gt;</td>
<td>9</td>
<td>12</td>
<td>0</td>
<td>10</td>
<td>2.5</td>
</tr>
</tbody>
</table>

Total (95% CI) | 571 | 193 | 100 | 19.80 (9.21–42.56) |

Total events | 211 | 0 | 0 | 0 |

Heterogeneity: \( \chi^2 = 89.42, df = 14, P = 0.80; I^2 = 0\% \)

Test for overall effect: \( Z = 7.65, P = 0.00001 \)

Figure 2 Fifteen studies, including 571 MM and 193 normal bone marrow cases, investigated \( p15 \) hypermethylation status between MM patients and normal individuals (pooled OR = 19.80, 95% CI: 9.21–42.56, \( P = 0.00001 \)).

**Abbreviations:** CI, confidence interval; MM, multiple myeloma; OR, odds ratio; df, degrees of freedom; M–H, Mantel–Haenszel.

indicates that \( p15 \) inactivation through hypermethylation plays an important role in the pathogenesis of MM. We further determined that \( p15 \) hypermethylation also occurs in MGS, which is significantly less than that in MM (OR = 2.25, 95% CI: 1.20–4.21, \( P = 0.01 \); the pooled frequency rate of the \( p15 \) hypermethylation in MM is 26.7% whereas in MGS it is 13.9%, as shown in Figure 3A, but higher than that in normal bone marrow (OR = 5.40, 95% CI: 1.09–26.86, \( P = 0.04 \)), as shown in Figure 3B.

We analyzed 179 MM patients pooled in five studies to assess whether or not the aberrant \( p15 \) hypermethylation in MM was associated with advanced stages of MM. As shown in Figure 4, aberrant \( p15 \) hypermethylation is not significantly higher in advanced MM (Stage III) than that in early-stage MM (Stages I and II) (OR = 1.17, 95% CI: 0.54–2.54, \( P = 0.69 \)). Staging of MM is the process of finding out the amount of malignant myeloma cells that have advanced; it relies mainly on levels of albumin and beta-2-microglobulin in the blood, platelet count, kidney function, and patient’s age. MM stages which are equivalent to progression are determined by evolving mutations and epigenetic mechanisms. Our results suggest that the inactivation of \( p15 \) gene expression by promoter hypermethylation may not play an important role in MM progression.

Finally, we performed sensitivity analyses, in which one study at a time was removed, to assess the result stability. The pooled ORs were not significantly changed, indicating the stability of our analyses. The funnel plots are largely symmetric (Figure 5), suggesting there were no publication biases in the meta-analysis of \( p15 \) hypermethylation and clinicopathological features.

**Discussion**

The \( p15 \) gene, along with \( p14 \) and \( p16 \), is the most prevalent hypermethylated cell cycle regulatory gene in tumorigenesis and progression of MM. We conducted this meta-analysis to determine the correlation between \( p15 \) hypermethylation and MM. Analysis of the pooled data showed that 1) significantly higher \( p15 \) hypermethylation was detected in MM than that in normal bone marrow; 2) \( p15 \) hypermethylation was also detected in MGS, but significantly less than that in MM; 3) \( p15 \) hypermethylation was also higher in MGS than that in normal bone marrow; and 4) \( p15 \) hypermethylation was not significantly higher in advanced MM than that in early-stage MM. Epigenetic changes contribute to tumorigenesis and affect initial steps in malignant transformation by altering genome stability and regulating gene expression. MM develops as a result...
Figure 3 (A) Six of included studies investigated $p15$ hypermethylation status between 315 patients with multiple myeloma (MM) and 101 MGUS (pooled OR=$2.25$, 95% CI=$1.20$–$4.21$, $P=0.01$). (B) Four of included studies investigated $p15$ hypermethylation status between 65 patients with MGUS and 33 normal bone marrow (pooled OR=$5.40$, 95% CI=$1.09$–$26.86$, $P=0.04$).

Abbreviations: CI, confidence interval; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; OR, odds ratio; df, degrees of freedom; M–H, Mantel–Haenszel.

Figure 4 The pooled OR from five studies including 179 MM patients. Aberrant $p15$ hypermethylation was not significantly higher in advanced MM (Stage III) than that in early-stage MM (Stage I and II) (OR=$1.17$, 95% CI=$0.54$–$2.54$, $P=0.69$).

Abbreviations: CI, confidence interval; MM, multiple myeloma; OR, odds ratio; df, degrees of freedom; M–H, Mantel–Haenszel.
stages of MM was not elucidated. The results from the current study demonstrates that the hypermethylation rate of \(p15\) gene promoter in MGUS was higher than that in normal bone marrow, indicating that \(p15\) promoter hypermethylation was an early event in myelomagenesis. We did not find that \(p15\) hypermethylation in MM was associated with advanced stage. These results also indicate that \(p15\) hypermethylation could potentially be an early event. The results that significantly higher \(p15\) hypermethylation was detected in MM than that in normal bone marrow and MGUS indicate that \(p15\) hypermethylation is common in MM. Since changes in \(p15\) hypermethylation are reversible, drug treatment through demethylation may be useful to delay carcinogenesis and progression. This approach may bring new direction and hope for MM treatment through gene-targeted therapy.

Progression from MGUS to MM appears to mirror the accumulation of genetic abnormalities, suggesting a stepwise progression of genetic and epigenetic changes.\(^3^4\) Hypermethylation of several tumor suppressors, such as \(p15\), \(ARF\), \(SOCS-1\), \(p27 KIP1\), \(RASSF1A\), non-receptor type 6 (SHP1), death-associated protein kinase, and \(TP73\) genes was reported in MGUS.\(^3^5\)\(^3^6\) Our meta-analysis showed that \(p15\) gene hypermethylation in MGUS is higher than that in normal cohort. Our results also showed that \(p15\) hypermethylation in MGUS was significantly less than that in MM. Therefore, hypermethylation of the \(p15\) gene could potentially be involved in the progression of MGUS to MM. In addition, combining \(p15\) with other tumor suppressor genes to develop several gene markers will be a valuable strategy for risk stratification to predict initial carcinogenesis and neoplastic progression of MM.

**Limitations**

This study has several potential limitations. First, the search strategy was restricted to articles published in English and Chinese. Articles with potentially high-quality data that were published in other languages were not included because of anticipated difficulties in obtaining accurate medical data.
translation. Second, the possibility of information and selection biases as well as unidentified confounders could not be completely excluded because all of the included studies were observational. Hence, caution should be taken when our findings are interpreted among the general populations. In addition, for MSP detection, it is usually to detect CpG island regions in the gene promoter or the first exon. The different location of detection sites may affect the methylation rate.

**Conclusion**

We performed a meta-analysis of 16 eligible studies. Our results demonstrated that $p15$ hypermethylation is significantly higher in MM than that in normal bone marrow, as well as in MGUS. However, aberrant $p15$ hypermethylation was not significantly higher in advanced MM than that in early-stage MM. The results of this meta-analysis suggest that $p15$ hypermethylation is associated with an increased risk in the progression of MGUS to MM. $p15$ hypermethylation, which induces the inactivation of $p15$ gene, plays an important role in the early tumorigenesis of MM and serves as a reputable prognostic marker and potential drug target.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


